BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 26823503)

  • 1. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
    Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
    Roder C; Bisdas S; Ebner FH; Honegger J; Naegele T; Ernemann U; Tatagiba M
    Eur J Surg Oncol; 2014 Mar; 40(3):297-304. PubMed ID: 24411704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
    Li YM; Suki D; Hess K; Sawaya R
    J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
    Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
    Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
    Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
    Oppenlander ME; Wolf AB; Snyder LA; Bina R; Wilson JR; Coons SW; Ashby LS; Brachman D; Nakaji P; Porter RW; Smith KA; Spetzler RF; Sanai N
    J Neurosurg; 2014 Apr; 120(4):846-53. PubMed ID: 24484232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma.
    Yong RL; Wu T; Mihatov N; Shen MJ; Brown MA; Zaghloul KA; Park GE; Park JK
    J Neurosurg; 2014 Oct; 121(4):802-9. PubMed ID: 25061868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.
    Fariña Nuñez MT; Franco P; Cipriani D; Neidert N; Behringer SP; Mader I; Delev D; Fung C; Beck J; Sankowski R; Nicolay NH; Heiland DH; Schnell O
    J Neurooncol; 2020 Jan; 146(2):381-387. PubMed ID: 31933259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging.
    Coburger J; Wirtz CR; König RW
    J Neurosurg Sci; 2017 Jun; 61(3):233-244. PubMed ID: 26149222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance.
    Kuhnt D; Becker A; Ganslandt O; Bauer M; Buchfelder M; Nimsky C
    Neuro Oncol; 2011 Dec; 13(12):1339-48. PubMed ID: 21914639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.
    Chaichana KL; Jusue-Torres I; Navarro-Ramirez R; Raza SM; Pascual-Gallego M; Ibrahim A; Hernandez-Hermann M; Gomez L; Ye X; Weingart JD; Olivi A; Blakeley J; Gallia GL; Lim M; Brem H; Quinones-Hinojosa A
    Neuro Oncol; 2014 Jan; 16(1):113-22. PubMed ID: 24285550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of re-operation on survival in patients with recurrent glioblastoma.
    Franceschi E; Bartolotti M; Tosoni A; Bartolini S; Sturiale C; Fioravanti A; Pozzati E; Galzio R; Talacchi A; Volpin L; Morandi L; Danieli D; Ermani M; Brandes AA
    Anticancer Res; 2015 Mar; 35(3):1743-8. PubMed ID: 25750337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
    Heßelmann V; Mager AK; Goetz C; Detsch O; Theisgen HK; Friese M; Schwindt W; Gottschalk J; Kremer P
    Rofo; 2017 Jun; 189(6):519-526. PubMed ID: 28591887
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
    Coburger J; Hagel V; Wirtz CR; König R
    PLoS One; 2015; 10(6):e0131872. PubMed ID: 26115409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of tumor resection for recurrent glioblastoma.
    Quick J; Gessler F; Dützmann S; Hattingen E; Harter PN; Weise LM; Franz K; Seifert V; Senft C
    J Neurooncol; 2014 Apr; 117(2):365-72. PubMed ID: 24535317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.